Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
Susanna B. Park,David Goldstein,Arun V. Krishnan,Cindy S.-Y. Lin,Michael Friedlander,James T. Cassidy,Martin Koltzenburg,Matthew C. Kiernan +7 more
Reads0
Chats0
TLDR
This review will address the increasing importance and challenge of chemotherapy‐induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers.Abstract:
With a 3-fold increase in the number of cancer survivors noted since the 1970s, there are now over 28 million cancer survivors worldwide. Accordingly, there is a heightened awareness of long-term toxicities and the impact on quality of life following treatment in cancer survivors. This review will address the increasing importance and challenge of chemotherapy-induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers. An overview of the diagnosis, symptomatology, and pathophysiology of chemotherapy-induced peripheral neuropathy will be provided, with a critical analysis of assessment strategies, neuroprotective approaches, and potential treatments. The review will concentrate on neuropathy associated with taxanes, platinum compounds, vinca alkaloids, thalidomide, and bortezomib, providing clinical information specific to these chemotherapies. CA Cancer J Clin 2013;63:419-437. ©2013 American Cancer Society, Inc.read more
Citations
More filters
Journal ArticleDOI
Reactive Oxygen Species (ROS)-Based Nanomedicine.
Bowen Yang,Yu Chen,Jianlin Shi +2 more
TL;DR: In this article, the intrinsic biochemical properties of reactive oxygen species (ROS) underlie the mechanisms that regulate various physiological functions of living organisms, and they play an essential role in regulating various physiological function.
Journal ArticleDOI
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.
Marta Seretny,Gillian L. Currie,Emily S. Sena,Sabrina Ramnarine,Robin Grant,Malcolm R. Macleod,Leslie A. Colvin,Marie Fallon +7 more
TL;DR: A systematic review of studies reporting the prevalence of Chemotherapy‐induced peripheral neuropathy identified 31 studies with data from 4179 patients and identified a number of genetic and clinical risk factors that require further study.
Journal ArticleDOI
Microbiota: a key orchestrator of cancer therapy.
Soumen Roy,Giorgio Trinchieri +1 more
TL;DR: The evidence for the ability of the microbiota to modulate chemotherapy, radiotherapy and immunotherapy is discussed with a focus on the microbial species involved, their mechanism of action and the possibility of targeting the microbiome to improve anticancer efficacy while preventing toxicity.
Journal ArticleDOI
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy.
Renata Zajączkowska,Magdalena Kocot-Kępska,Wojciech Leppert,Anna Wrzosek,Joanna Mika,Jerzy Wordliczek +5 more
TL;DR: A better understanding of the risk factors and underlying mechanisms of CIPN is needed to develop effective preventive and therapeutic strategies and the neurotoxicity mechanisms of the most common antineoplastic agents are reviewed.
Journal ArticleDOI
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Hana Starobova,Irina Vetter +1 more
TL;DR: This review focusses on the commonly used antineoplastic substances oxaliplatin, cisPlatin, vincristine, docetaxel, and paclitaxel which interfere with the cancer cell cycle—leading to cell death and tumor degradation—and cause severe acute and chronic peripheral neuropathies.
References
More filters
Journal ArticleDOI
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
Roberto Petrioli,Alessandra Pascucci,Edoardo Francini,Stefania Marsili,Angela Sciandivasci,Rossana Tassi,Serenella Civitelli,G. Tanzini,Marco Lorenzi,Guido Francini +9 more
TL;DR: This study suggests that l-HOP as a continuous 6-h infusion is useful in preventing and reducing acute and possibly chronic l- HOP induced neurotoxicity in patients with colon and gastric cancer receiving FOLFOX-4 regimen as adjuvant treatment.
Journal ArticleDOI
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
Dina M. Kweekel,Hans Gelderblom,Ninja Antonini,Tahar van der Straaten,Johan W. R. Nortier,Cornelis J. A. Punt,Henk-Jan Guchelaar +6 more
TL;DR: The results of this study indicate that the GSTP1 genotype is not predictive for progression-free survival or overall survival in ACC patients treated with CAPOX, and overall neurotoxicity and neurotoxicity in patients receiving 500 mg/m(2) of oxaliplatin was not associated with GSTP 1 genotype.
Journal ArticleDOI
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial
Martin Kropff,Honorata Giongco Baylon,Jens Hillengass,Tadeusz Robak,Roman Hájek,Peter Liebisch,Stefan Goranov,Cyrille Hulin,Joan Bladé,Tommaso Caravita,Hervé Avet-Loiseau,Thomas Moehler,Claire Pattou,Lela M. Lucy,Elisabeth Kueenburg,Axel Glasmacher,Robert Zerbib,Thierry Facon +17 more
TL;DR: Thalidomide monotherapy may be considered an effective salvage therapy option for patients with relapsed/refractory multiple myeloma, particularly those with a good prognosis and those who have received two or three prior therapies.
Journal ArticleDOI
The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS.
Christopher J. Klein,Joon Shik Moon,Michelle L. Mauermann,Steven R. Zeldenrust,Yanhong Wu,Angela Dispenzieri,Peter J. Dyck +6 more
TL;DR: Clinical neuropathy presentations of WM and IgM-MGUS are similar and likely related to comparable axonal loss in both conditions, and evidence of demyelination was found by electrophysiologic studies much more commonly in IgM -MGUS.
Related Papers (5)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman,Christina Lacchetti,Robert H. Dworkin,Ellen M. Lavoie Smith,Jonathan Bleeker,Guido Cavaletti,Cynthia Chauhan,Patrick Gavin,Antoinette Lavino,Maryam B. Lustberg,Judith A. Paice,Bryan P. Schneider,Mary Lou Smith,Thomas J. Smith,Shelby A. Terstriep,Nina D. Wagner-Johnston,Kate Bak,Charles L. Loprinzi +17 more